Richard A. Heyman, Director at Enliven Therapeutics, Inc. (ELVN), sold 1,230 shares at $26.46 ($33K) on 2026-01-20, disclosed to the SEC on 2026-01-22.
Scheduled sale ($33k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $26.46 | 512 | $14K | 41.2% |
| 2 | $26.96 | 718 | $19K | 58.8% |
| Total | $26.75 avg | 1,230 | $33K | 100% |
| Filing → |
| ELVN | SELL | 2026-02-19 | $32K | — | Filing → |
| ORIC | SELL | 2026-01-20 | $80K | — | Filing → |
| ELVN | SELL | 2026-01-12 | $656K | — | Filing → |